MCID: DBT009
MIFTS: 64

Diabetes Mellitus

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Diabetes Mellitus

MalaCards integrated aliases for Diabetes Mellitus:

Name: Diabetes Mellitus 12 74 29 54 6 43 15 17 71 32
Diabetes 6 42 3 15 39 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9351
ICD9CM 34 250
MeSH 43 D003920
NCIt 49 C2985
SNOMED-CT 67 73211009
UMLS 71 C0011847 C0011849

Summaries for Diabetes Mellitus

MedlinePlus : 42 Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes. Over time, having too much glucose in your blood can cause serious problems. It can damage your eyes, kidneys, and nerves. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes. Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your blood glucose level and take medicine if prescribed. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, also known as diabetes, is related to neonatal diabetes mellitus and type 1 diabetes mellitus 11, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus is KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Nicorandil and Iodine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes.

Disease Ontology : 12 A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

CDC : 3 Diabetes is a chronic (long-lasting) disease that affects how your body turns food into energy. There are three main types of diabetes: type 1, type 2, and gestational diabetes (diabetes while pregnant).

Novus Biologicals : 55 Diabetes is a disease in which the body does not produce or properly use insulin. There are four major types of diabetes: Type 1, Type 2, Gestational and Pre-Diabetes. Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disease resulting when one's own immune system destroys insulin-producing beta cells in the pancreas. This causes the pancreas to produce little or no insulin. In type 2 diabetes, the body either does not produce enough insulin or beta cells ignore insulin. Gestational diabetes refers to high glucose levels caused by pregnancy. Pre-diabetes is a condition in which blood glucose levels are high, but not high enough for the diagnosis of type 2 diabetes.

Wikipedia : 74 Diabetes mellitus (DM), commonly known as diabetes, is a group of metabolic disorders characterized by a... more...

Related Diseases for Diabetes Mellitus

Diseases in the Diabetes Mellitus family:

Diabetes Mellitus, Type I Diabetes Mellitus, Congenital Autoimmune
Type 1 Diabetes Mellitus 2 Type 1 Diabetes Mellitus 3
Type 1 Diabetes Mellitus 4 Type 1 Diabetes Mellitus 5
Type 1 Diabetes Mellitus 6 Type 1 Diabetes Mellitus 7
Type 1 Diabetes Mellitus 8 Type 1 Diabetes Mellitus 10
Type 1 Diabetes Mellitus 11 Type 1 Diabetes Mellitus 12
Type 1 Diabetes Mellitus 13 Type 1 Diabetes Mellitus 15
Type 1 Diabetes Mellitus 17 Type 1 Diabetes Mellitus 18
Rare Diabetes Mellitus Type 1 Rare Diabetes Mellitus Type 2
Rare Diabetes Mellitus

Diseases related to Diabetes Mellitus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3586)
# Related Disease Score Top Affiliating Genes
1 neonatal diabetes mellitus 35.8 WFS1 KCNJ11 HNF1A
2 type 1 diabetes mellitus 11 35.2 HNF1A CELA2A
3 diabetes mellitus, noninsulin-dependent 35.2 WFS1 PVT1 MIR17 MIR140 KCNJ11 HNF1A
4 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 35.1 WFS1 KCNJ11
5 rare diabetes mellitus type 2 35.1 WFS1 KCNJ11 HNF1A
6 maturity-onset diabetes of the young, type 2 34.3 WFS1 KCNJ11 HNF1A
7 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 33.7 KCNJ11 HNF1A
8 maturity-onset diabetes of the young, type 6 33.6 KCNJ11 HNF1A
9 maturity-onset diabetes of the young, type 4 33.5 KCNJ11 HNF1A
10 monogenic diabetes 32.3 WFS1 KCNJ11 HNF1A
11 insulinoma 32.3 WFS1 MEN1 HNF1A
12 bile duct disease 32.1 MIR30E MIR17 MIR145 MIR140
13 non-alcoholic fatty liver disease 32.1 MIR17 MIR155 MIR140 MIR132
14 hyperinsulinemic hypoglycemia 32.1 PMM2 MEN1 KCNJ11 HNF1A
15 body mass index quantitative trait locus 11 32.0 MIR30E MIR17 MIR155 MIR140 KCNJ11 HNF1A
16 arteries, anomalies of 31.5 MIR30E MIR17 MIR155 MIR145 MIR140 MIR132
17 coronary heart disease 1 31.5 MIR17 MIR155 MIR145 MIR140 CELA2A CDKN2B-AS1
18 glucose metabolism disease 31.3 MIR17 MIR155 MIR140 KCNJ11
19 colonic disease 31.1 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
20 prostate disease 31.1 MIR99A MIR30E MIR17 MIR145 MIR140 MALAT1
21 hypertension, essential 31.1 MIR30E MIR17 MIR155 MIR145 MEN1 CELA2A
22 rectum cancer 30.9 MIR99A MIR17 MIR145
23 cardiovascular system disease 30.9 MIR17 MIR155 MIR145 CDKN2B-AS1
24 maturity-onset diabetes of the young, type 13 30.8 KCNJ11 HNF1A
25 pituitary adenoma 30.7 MIR197 MIR132 MEN1 MALAT1
26 polymyositis 30.5 MIR155 MIR132
27 biliary tract disease 30.5 MIR30E MIR17 MIR145 MIR140
28 connective tissue disease 30.4 MIR30E MIR17 MIR155 MIR145 MIR140
29 ovarian disease 30.3 MIR17 MIR145 MIR140 MIR132
30 lymphoma, hodgkin, classic 30.3 PVT1 MIR155 MIR140
31 pancreas disease 30.2 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
32 diffuse large b-cell lymphoma 30.2 MIR99A MIR17 MIR155 MIR145
33 pancreatic ductal adenocarcinoma 30.2 PVT1 MIR375 MIR155 MIR145 MALAT1
34 gastrointestinal system disease 30.2 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
35 bladder disease 30.2 MIR99A MIR17 MIR145 MIR140
36 breast disease 30.1 MIR30E MIR17 MIR155 MIR145 MIR140
37 chromosomal disease 30.0 MIR17 MIR155 MIR140
38 b-cell lymphoma 30.0 TUG1 PVT1 MIR17 MIR155 MALAT1
39 bone inflammation disease 30.0 MIR17 MIR155 MIR140
40 spinal disease 30.0 MIR30E MIR17 MIR155 MIR140
41 nasopharyngeal carcinoma 29.8 PVT1 MIR30E MIR17 MALAT1 CDKN2B-AS1
42 oral cavity cancer 29.8 MIR99A MIR17 MIR145 MIR140
43 myeloma, multiple 29.8 TUG1 PVT1 MIR17 MIR145 MIR140 MALAT1
44 nervous system disease 29.7 MIR30E MIR17 MIR155 MIR145 MIR140 MIR132
45 gallbladder cancer 29.7 TUG1 MIR145 MALAT1 CDKN2B-AS1
46 esophageal disease 29.7 MIR99A MIR17 MIR145 MIR140
47 muscular dystrophy, duchenne type 29.6 MIR30E MIR197 MIR155 MIR134
48 glioma 29.6 PVT1 MIR17 MIR140 MALAT1 CDKN2B-AS1
49 laryngeal squamous cell carcinoma 29.5 MIR155 MALAT1 CDKN2B-AS1
50 leukemia, chronic lymphocytic 29.5 MIR30E MIR17 MIR155 MIR145 MIR140 MIR134

Graphical network of the top 20 diseases related to Diabetes Mellitus:



Diseases related to Diabetes Mellitus

Symptoms & Phenotypes for Diabetes Mellitus

UMLS symptoms related to Diabetes Mellitus:


tremor, angina pectoris, equilibration disorder, symptoms

Drugs & Therapeutics for Diabetes Mellitus

Drugs for Diabetes Mellitus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 948)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
2
Iodine Approved, Investigational Phase 4 7553-56-2 807
3
Povidone Approved Phase 4 9003-39-8
4
Povidone-iodine Approved Phase 4 25655-41-8
5
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
6
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
9
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
12
Adalimumab Approved Phase 4 331731-18-1 16219006
13
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
14
Thrombin Approved, Investigational Phase 4
15
Glucagon Approved Phase 4 16941-32-5
16
Insulin glulisine Approved Phase 4 207748-29-6
17
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
18
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
19
Pramlintide Approved, Investigational Phase 4 151126-32-8
20
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
21
Gliquidone Approved, Investigational Phase 4 33342-05-1 91610
22
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
23
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
Captopril Approved Phase 4 62571-86-2 44093
26
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
27
Magnesium oxide Approved Phase 4 1309-48-4 14792
28
leucovorin Approved Phase 4 58-05-9 6006 143
29
Bilberry Approved, Experimental Phase 4
30
Fenofibrate Approved Phase 4 49562-28-9 3339
31
Lacidipine Approved, Investigational Phase 4 103890-78-4
32
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
33
Propranolol Approved, Investigational Phase 4 525-66-6 4946
34
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
35
Enalaprilat Approved Phase 4 76420-72-9 6917719
36
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
37
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
38
Sodium citrate Approved, Investigational Phase 4 68-04-2
39
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
40
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
41
Trimetazidine Approved, Investigational Phase 4 5011-34-7
42
Lactulose Approved Phase 4 4618-18-2 11333
43 Lycopene Approved, Investigational Phase 4 502-65-8 53477748
44
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
45
Citalopram Approved Phase 4 59729-33-8 2771
46
Eplerenone Approved Phase 4 107724-20-9 150310 443872
47
Ephedrine Approved Phase 4 299-42-3 9294
48
Pseudoephedrine Approved Phase 4 90-82-4 7028
49
Norepinephrine Approved Phase 4 51-41-2 439260
50
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
2 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
3 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
4 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
5 A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists Unknown status NCT00144144 Phase 4 Angiotensin II receptor antagonists, Calcium channel blocker
6 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4 Repaglinide
7 The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Unknown status NCT02372630 Phase 4 Linagliptin;Placebo
8 Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients Unknown status NCT01768208 Phase 4 Saxagliptin
9 Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study Unknown status NCT00427271 Phase 4 aspirin
10 A Randomized, Double-blind, Active Control, Parallel Group, Exploratory Phase IV Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin in Patients With Inadequately Controlled Type2 Diabetes Mellitus in Metformin Only Treatment Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
11 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
12 Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
13 Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose? Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
14 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
15 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
16 Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
17 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
18 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
19 A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
20 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
21 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4 Metformin;Metformin;Vildagliptin;Glimepiride
22 The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia in Patients With Type 2 Diabetes Mellitus Unknown status NCT03120299 Phase 4 Omega-3 fatty acid;Placebos
23 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
24 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
25 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
26 Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study) Unknown status NCT03328845 Phase 4 Toujeo SoloStar;Tresiba;Humalog Kwikpen;NovoRapid;Apidra
27 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
28 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
29 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
30 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
31 Effect of Metformin as add-on Therapy on Glycemic Control and Other Diabetes‑Related Outcomes in Type 1 Diabetic Patients:a Open-label,Self-control Study Unknown status NCT03590262 Phase 4 Metformin
32 Effects of New Longacting Insulin Analogs on Metabolic Control, Endogenous Insulin Production, GH/IGF-I Axis and Quality of Life - Comparison of NPH, Glargine Och Detemir Insulin From the Debut of Type 1 Diabetes Mellitus in Adolescents Unknown status NCT01271517 Phase 4 NPH insulin;Glargine;Detemir
33 Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
34 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
35 Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Unknown status NCT03244241 Phase 4 Insulin Degludec 100 UNT/ML [Tresiba]
36 An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
37 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
38 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
39 Efficacy of Combination of Glucometer and Mobile-phone Based Data Transfer System on Glycemic Control in Patients With Diabetes Unknown status NCT02769377 Phase 4
40 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
41 A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy Unknown status NCT03320031 Phase 4 Linagliptin;Humalog Mix 75/25
42 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
43 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
44 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
45 Effect of Reconstitute Multiple Grain on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Unknown status NCT00337337 Phase 4
46 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
47 A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes Unknown status NCT00788840 Phase 4 Insulatard;Detemir
48 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
49 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
50 A Randomized, Non-inferiority, Open-label Clinical Trial to Evaluate the Safety and Efficacy of GAcarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes in Chinese Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin

Search NIH Clinical Center for Diabetes Mellitus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


CHROMIUM PICOLINATE

Cochrane evidence based reviews: diabetes mellitus

Genetic Tests for Diabetes Mellitus

Genetic tests related to Diabetes Mellitus:

# Genetic test Affiliating Genes
1 Diabetes Mellitus 29

Anatomical Context for Diabetes Mellitus

MalaCards organs/tissues related to Diabetes Mellitus:

40
Heart, Kidney, Testes, Endothelial, Liver, Bone, Pancreas

Publications for Diabetes Mellitus

Articles related to Diabetes Mellitus:

(show top 50) (show all 52559)
# Title Authors PMID Year
1
Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization: From TSOC ACS-DM registry. 42
32384446 2020
2
Impact of mobile phone text messaging intervention on adherence among patients with diabetes in a rural setting: A randomized controlled trial. 42
32195927 2020
3
Sounding the alarm on rising diabetes-related amputations. 42
32392480 2019
4
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. 61 54
20415560 2010
5
Polymorphisms of the UCP2 gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. 61 54
19681913 2010
6
Plasma copeptin and the risk of diabetes mellitus. 54 61
20439785 2010
7
Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies. 54 61
20233909 2010
8
CTLA4 promoter polymorphisms are associated with canine diabetes mellitus. 54 61
20196832 2010
9
Comparative study of atherosclerotic parameters in Mongolian and Japanese patients with hypertension and diabetes mellitus. 54 61
20124737 2010
10
Butyrylcholinesterase and diabetes mellitus in the CHE2 C5- and CHE2 C5+ phenotypes. 54 61
20414550 2010
11
Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: correlation with antioxidant activity. 61 54
20143968 2010
12
[A target of PPARgamma agonist: diabetes mellitus]. 61 54
20158098 2010
13
[Metabolic syndrome, insulin resistance and cardiovascular disease in type-1 diabetes mellitus]. 54 61
20414537 2010
14
Acquired reactive perforating collagenosis in an insulin dependent diabetes mellitus patient. 54 61
20469788 2009
15
Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus. 61 54
19373836 2009
16
Motilin concentrations in relation to gastro intestinal dysmotility in diabetes mellitus. 54 61
19782932 2009
17
Cystatin C levels are unaltered in patients with diabetes mellitus and normal renal function. 54 61
19644487 2009
18
Haptoglobin genotype and endothelial function in diabetes mellitus: a pilot study. 61 54
19347351 2009
19
Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2). 61 54
19329212 2009
20
[Diabetes susceptibility genes]. 54 61
19507498 2009
21
Aortic ER stress in streptozotocin-induced diabetes mellitus in APA hamsters. 61 54
19448334 2009
22
Overexpression of heme oxygenase-1 in coronary atherosclerosis of Japanese autopsies with diabetes mellitus: Hisayama study. 54 61
18620357 2009
23
HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. 61 54
19252740 2009
24
MicroRNA expression in human omental and subcutaneous adipose tissue. 46
19259271 2009
25
Serum gamma-glutamyl transferase level and diabetes mellitus among US adults. 54 61
19449164 2009
26
WFS1 mutations are frequent monogenic causes of juvenile-onset diabetes mellitus in Lebanon. 54 61
18806274 2008
27
Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. 61 54
18706702 2008
28
Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. 61 54
18806525 2008
29
Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. 54 61
18514089 2008
30
The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. 54 61
18317479 2008
31
Monocyte attachment and migration through collagen IV in diabetes mellitus. 54 61
18443419 2008
32
Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. 61 54
18423055 2008
33
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. 61 54
18060660 2008
34
The role of K121Q ENPP1 polymorphism in diabetes mellitus and its complications. 54 61
18176722 2008
35
Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. 61 54
18691043 2008
36
Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus. 61 54
18082523 2007
37
Evaluation of inhaled insulin therapy for diabetes mellitus. 61 54
17703168 2007
38
N-acetyltransferase 2 polymorphism in patients with diabetes mellitus. 61 54
16397907 2007
39
HNF4A genetic variants: role in diabetes. 54 61
17563455 2007
40
Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. 61 54
17630927 2007
41
Insulin analogues: new dimension of management of diabetes mellitus. 61 54
17344794 2007
42
[Antihypertensive agents and the risk of new onset diabetes mellitus]. 54 61
17212194 2006
43
[Aceruloplasminemia (hereditary ceruloplasmin deficiency) and diabetes mellitus]. 61 54
17022509 2006
44
Estrogen receptors: new players in diabetes mellitus. 54 61
16890492 2006
45
[Calcium homeostasis and diabetes mellitus]. 54 61
16883034 2006
46
Diabetes, nephropathy, and the renin system. 54 61
16601578 2006
47
Reactive oxygen species, hydrogen peroxide, catalase and diabetes mellitus. 54 61
17207310 2006
48
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. 54 61
16442340 2006
49
Calpain 10 and development of diabetes mellitus in cystic fibrosis. 61 54
16377260 2006
50
Oxidative inactivation of paraoxonase--implications in diabetes mellitus and atherosclerosis. 61 54
16112460 2005

Variations for Diabetes Mellitus

ClinVar genetic disease variations for Diabetes Mellitus:

6 (show all 22) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CELA2A NM_033440.3(CELA2A):c.209C>T (p.Thr70Met)SNV Pathogenic 633595 1:15788135-15788135 1:15461640-15461640
2 CELA2A NM_033440.3(CELA2A):c.253C>A (p.Leu85Met)SNV Pathogenic 633593 1:15789253-15789253 1:15462758-15462758
3 CELA2A NM_033440.3(CELA2A):c.361G>A (p.Asp121Asn)SNV Pathogenic 633592 1:15789885-15789885 1:15463390-15463390
4 CELA2A NM_033440.3(CELA2A):c.639+1G>CSNV Pathogenic 633594 1:15792640-15792640 1:15466145-15466145
5 HNF1A NM_000545.8(HNF1A):c.1139del (p.Val380fs)deletion Pathogenic 916726 12:121434375-121434375 12:120996572-120996572
6 HNF1A NM_000545.8(HNF1A):c.1310-1G>ASNV Pathogenic 916727 12:121435276-121435276 12:120997473-120997473
7 WFS1 NM_006005.3(WFS1):c.1362_1377del (p.Pro453_Tyr454insTer)deletion Pathogenic 916728 4:6302884-6302899 4:6301157-6301172
8 PMM2 NM_000303.3(PMM2):c.422G>A (p.Arg141His)SNV Pathogenic 7706 rs28936415 16:8905010-8905010 16:8811153-8811153
9 KCNJ11 NM_000525.3(KCNJ11):c.601C>T (p.Arg201Cys)SNV Pathogenic 8668 rs80356625 11:17409038-17409038 11:17387491-17387491
10 KCNJ11 NM_000525.3(KCNJ11):c.964G>A (p.Glu322Lys)SNV Pathogenic 21203 rs193929355 11:17408675-17408675 11:17387128-17387128
11 KCNJ11 NM_000525.3(KCNJ11):c.988T>C (p.Tyr330His)SNV Pathogenic 158688 rs587783675 11:17408651-17408651 11:17387104-17387104
12 KCNJ11 NM_000525.3(KCNJ11):c.685G>A (p.Glu229Lys)SNV Pathogenic 158683 rs587783673 11:17408954-17408954 11:17387407-17387407
13 KCNJ11 NM_000525.3(KCNJ11):c.679G>A (p.Glu227Lys)SNV Pathogenic 158682 rs587783672 11:17408960-17408960 11:17387413-17387413
14 MEN1 NM_000244.3(MEN1):c.669+1deldeletion Pathogenic 374107 rs1057518903 11:64575362-64575362 11:64807890-64807890
15 PMM2 NM_000303.3(PMM2):c.584A>G (p.His195Arg)SNV Likely pathogenic 812999 16:8906908-8906908 16:8813051-8813051
16 KCNJ11 NM_000525.3(KCNJ11):c.498C>G (p.Cys166Trp)SNV Likely pathogenic 158676 rs587783669 11:17409141-17409141 11:17387594-17387594
17 INS , INS-IGF2 NM_000207.3(INS):c.174del (p.Glu59fs)deletion Likely pathogenic 916729 11:2182028-2182028 11:2160798-2160798
18 ARMC9 NM_001352754.2(ARMC9):c.636G>C (p.Gln212His)SNV Conflicting interpretations of pathogenicity 739322 2:232099950-232099950 2:231235237-231235237
19 ABCC8 NM_000352.6(ABCC8):c.1562G>A (p.Arg521Gln)SNV Conflicting interpretations of pathogenicity 157683 rs368114790 11:17464335-17464335 11:17442788-17442788
20 KCNJ11 NM_000525.3(KCNJ11):c.463G>A (p.Val155Met)SNV Uncertain significance 158675 rs587783668 11:17409176-17409176 11:17387629-17387629
21 KLF11 NM_003597.5(KLF11):c.1077G>A (p.Met359Ile)SNV Uncertain significance 330636 rs146486664 2:10188541-10188541 2:10048414-10048414
22 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro)SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468

Copy number variations for Diabetes Mellitus from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 110220 17 3154257 3410803 Deletion HNF1b Diabetes mellitus
2 110369 17 31923035 33323544 Deletion HNF1B Diabetes mellitus
3 110541 17 33120546 33179209 Deletion HNF1B Diabetes mellitus
4 203632 1 158846514 158883705 Rearrangement SLAM Diabetes mellitus
5 225144 7 43300000 45400000 Gain or loss GCK Diabetes mellitus

Expression for Diabetes Mellitus

Search GEO for disease gene expression data for Diabetes Mellitus.

Pathways for Diabetes Mellitus

Pathways related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 MIR99A MIR375 MIR30E MIR17 MIR155 MIR145
2 11.18 MIR375 MIR30E MIR17 MIR132

GO Terms for Diabetes Mellitus

Cellular components related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR99A MIR375 MIR30E MIR197 MIR17 MIR155

Biological processes related to Diabetes Mellitus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.78 MIR17 MIR155 MIR132 CDKN2B-AS1
2 cellular response to hypoxia GO:0071456 9.62 MIR17 MIR155 MIR140 MALAT1
3 positive regulation of macrophage activation GO:0043032 9.49 MIR155 MIR145
4 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.46 MIR17 MIR155
5 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.43 MIR17 MIR155
6 negative regulation of sprouting angiogenesis GO:1903671 9.43 MIR375 MIR30E MIR17
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.4 MIR17 MIR155
8 negative regulation of interleukin-8 production GO:0032717 9.37 MIR155 MIR132
9 miRNA mediated inhibition of translation GO:0035278 9.35 MIR17 MIR155 MIR145 MIR134 MIR132
10 negative regulation of vascular endothelial growth factor production GO:1904046 9.33 MIR17 MIR140 MIR134
11 gene silencing by miRNA GO:0035195 9.32 MIR99A MIR375 MIR30E MIR197 MIR17 MIR155

Molecular functions related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
2 RNA polymerase II complex binding GO:0000993 9.13 MIR375 MIR145 MIR140

Sources for Diabetes Mellitus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....